Publikationen
CEBIO veröffentlicht regelmäßig Beiträge zu Liquid Biopsy, Referenzmaterialien und molekularer Diagnostik.
Bitte wählen Sie aus oder informieren Sie sich über aktuelle Veröffentlichungen.
Datei gefunden.Dateien gefunden.
Market-Ready Cell Line-derived cfDNA Reference
Materials for Liquid Biopsy Quality Assurance
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
Market-Ready Cell Line-derived cfDNA Reference
Materials for Liquid Biopsy Quality Assurance
Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – a CEPAC-TDM biomarker substudy.
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
